January 17, 2017 ReSeqTB Data Platform Now Available to Public January 17, 2017 TUCSON, Ariz., January 17, 2017 —The Rapid Drug Susceptibility Testing Consortium, coordinated by
October 25, 2016 TB-ReFLECT: A Collaborative Effort to Enhance TB Clinical Research Oct 25, 2016 TB-ReFLECT: A Collaborative Effort to Enhance TB Clinical Research TUCSON, Ariz., October 25, 2016 —
October 24, 2016 Advancing Tuberculosis Drug Regimen Development through Innovative Quantitative Translational Pharmacology Methods and Approaches
January 10, 2016 Population-Based Resistance of Mycobacterium Tuberculosis Isolates to Pyrazinamide and Fluoroquinolones: Results from a Multicountry Surveillance Project
June 6, 2016 C-Path and CDISC Announce Updated Therapeutic Area Standard for TB June 6, 2016 C-Path and CDISC Announce Updated Therapeutic Area Standard for TB TUCSON, Ariz., and AUSTIN, Texas –
January 4, 2016 Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects
January 4, 2016 Tuberculosis–Advances in Development of New Drugs, Treatment Regimens, Host-Directed Therapies, and Biomarkers
February 26, 2016 Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development
